Articles

RSS

Click Here To Download:
•Poster: Controlled Release Of Tamsulosin Hydrochloride Using EUDRAGIT® Polymers

By Evonik Röhm GmbH

Multiparticulate systems disperse freely in the gastrointestinal tract maximizing drug absorption, reduces peak plasma fluctuations and minimize side effects. It also helps in avoiding high local concentrations of drug.1–4 Tamsulosin hydrochloride, a selective adrenoreceptor blocking agent is prescribed in benign prostatic hyperplasia. The daily recommended dose of tamsulosin hydrochloride is 0.4–0.8 mg, highlighting its potent nature. Formulation of tamsulosin hydrochloride as a controlled release dosage forms is essential to overcome side effects like orthostatic hypotension. The present study details two approaches to prepare controlled release multiparticulate system of tamsulosin hydrochloride. The first approach uses aqueous polymeric dispersion of pH independent polymer, EUDRAGIT® NE 30 D in top spray granulation. In the second approach, aqueous dispersion of anioinc methacrylic polymer, EUDRAGIT® L 30 D-55 has been used in rotor granulation for obtaining the pellets

Click Here To Download:
•Poster: Controlled Release Of Tamsulosin Hydrochloride Using EUDRAGIT® Polymers